Mainz Biomed Provides Full Year 2022 Financial Results
Mainz Biomed N.V. announced financial results for the fiscal year ended December 31, 2022.
Mainz Biomed Provides Full Year 2022 Financial Results Read More »
Uncategorized
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma plc announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE – China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease.
YDS Pharmatech’s New Generative Diffusion Model Significantly Improves Structure-Based PROTAC Optimization and Ternary Interaction Analysis; Presentation at Drug Discovery Chemistry 2023 Conference
A groundbreaking study by a team of scientists at YDS Pharmatech, Inc. has introduced an innovative Generative Diffusion Model for sampling ensembles of degrader-induced ternary interactions, enabling a more effective approach to structure-based optimization of Proteolysis Targeting Chimeras.
GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors
GC Genome Corporation announced the publication of a new study in Radiation Oncology Journal, which demonstrates the feasibility of cell-free DNA monitoring to predict treatment response and detect minimal residual disease after radiation therapy in solid tumor patients using I-score, a tool for calculating genomic instabilities developed by GC Genome.
Syncell Showcases Pioneering Microscopy-Guided Subcellular Protein Scooping Technology at the AACR Annual Meeting 2023
Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, will be exhibiting and presenting a poster at the AACR Annual Meeting 2023 in Orlando, FL. Syncell’s Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification.
HCmed Appoints New Chief Scientific Officer
2HCmed Innovations Co., Ltd., a contract development and manufacturing organization, announced the appointment of Gunilla Petersson, Ph.D. as the new Chief Scientific Officer.
Sobi to streamline nirsevimab contractual arrangements
Sobi® announced a streamlining and simplification of the contractual economics for nirsevimab.
Sobi to streamline nirsevimab contractual arrangements Read More »
FDA Action Alert: Alvotech, Otsuka and More
The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.
Ciclo de entrevistas: “Invisibles” | Dra. Irma Mendoza: “Quisiera estimular a los médicos jóvenes a que se animen a salir de las ciudades”
Atiende en la región de El Soberbio Misiones, en cuatro centros de atención primaria y en diez aldeas de la comunidad mbya. Se instaló para “volver a los orígenes” e intercambiar saberes.
Mayor prevalencia en mujeres | Infarto de miocardio con arterias coronarias no obstruidas
El manejo de esta entidad varía según el mecanismo subyacente por lo que se recomiendan enfoques sistémicos para el diagnóstico